Pharmacokinetics of LCP-Tacro(TM) Once Daily And Prograf® Twice A Day in Adult De Novo Kidney Transplant Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

February 28, 2010

Study Completion Date

February 28, 2010

Conditions
Kidney FailureRenal Failure
Interventions
DRUG

Tacrolimus (Tacro™)

"The initial dose at 0.14 mg/kg (daily dose for African-American is 0.17 mg/kg), oral in the morning (before noon) within 12 hours after transplantation. Subsequent doses adjusted to maintain a target tacrolimus trough level of 7 - 20 ng/mL for (PK) phase of the study (through Study Day 14). Post PK maintenance phase of the study and remain on assigned study drug until Study Day 360. Dose of study drug was adjusted to maintain tacrolimus trough levels between 5 - 20 ng/mL from Day 15 until Day 90 and then between 5 - 15 ng/mL for the remainder of the study according to local standard of care.~Other Names:~Tacrolimus modified-release"

DRUG

Prograf

"Prograf® capsules, twice daily: Starting total daily dose of 0.10 mg/kg administered in two equally divided doses, morning and evening, per product labeling. Subsequent doses adjusted to maintain a target whole blood tacrolimus trough level of 7 - 20 ng/mL for the remainder of the pharmacokinetic (PK) phase of the study (through Study Day 14). Post PK patient enter the maintenance phase of the study and remain on assigned study drug until Study Day 360. Dose of study drug was adjusted to maintain tacrolimus trough levels between 5 - 20 ng/mL from Day 15 until Day 90 and then between 5 - 15 ng/mL for the remainder of the study according to local standard of care.~Other name: tacrolimus"

Trial Locations (1)

45267

University of Cincinnati, Cincinnati

All Listed Sponsors
collaborator

CTI Clinical Trial and Consulting Services

OTHER

collaborator

Aptuit

INDUSTRY

lead

Veloxis Pharmaceuticals

INDUSTRY